John Crumpler


Chairman of the Board of Directors

John Crumpler

John Crumpler co-founded Hatteras Venture Partners in 2000 after a successful career as a technology entrepreneur. At Hatteras, John is responsible for the firm’s investments in healthcare and life science information technology, and overall fund operations. He was founder and CEO of E-Comm, Inc., a software development and services firm specializing in remote and mobile computing that was acquired by XcelleNet. John ran the services division of XcelleNet until the company was acquired by Sterling Commerce.

John served on the boards of Synthematix and Clinverse, and currently serves on the boards of Medfusion, Jumo Health, Wildflower Health, Bivarus and Clinipace Worldwide. At Clinipace John has helped lead the transformation of Clinipace from a pure software company to a full-service digital CRO. He holds an A.B. from Harvard University.

Community and Board Engagements:

Throughout his career John has been active in government and public policy at the state and federal levels. A recipient of the Lyndhurst Prize, John served on the N. C. Economic Development Board, the state’s Clean Water Management Trust Fund board of directors, and as a trustee of the University of North Carolina School of the Arts. He currently serves on the board of the Council for Entrepreneurial Development and as a director of SouthLight Healthcare.

Kenneth B. Lee, Jr.


Secretary of the Board of Directors

Kenneth B. Lee, Jr.

Kenneth B. Lee, Jr. is involved in deal sourcing, investment decisions, board work, and exit strategies as a general partner of HVP III. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and valuation of Hatteras investments. Ken is the former co-head of International Life Sciences for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world

He got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the firm’s national life sciences practice from his location in the San Francisco Bay Area, he advised numerous high profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA, and Collagen.

Ken served on the Board of Directors of Clinverse and is Chairman of the Board of Clinipace. He graduated with a BA from Lenoir-Rhyne College and has an MBA from the University of North Carolina at Chapel Hill.

Community and Board Engagements:

Ken is a nationally-recognized financial matters expert and serves on the boards of Biocryst and Aralez, two publicly held biotech companies. He formerly served on the boards of Abgenix, CV Therapeutics, Inspire Pharmaceuticals (where he served as Chairman), Maxygen and OSI Pharmaceuticals. Ken also serves on the Board of the North Carolina Medical Foundation.

David W. Jessen, CPA


Treasurer of the Board of Directors

David W. Jessen, CPA

David Jessen is a retired partner from the international accounting firm Ernst & Young. Over the course of his 35-year career, he served as Director of Tax, Carolinas’ and Southeast Region Director of Entrepreneurial Services, and Office Managing Partner. David provided tax and financial consulting services to public and private corporations in pharmaceutical, biotech, manufacturing, telecom, real estate, and other industries. His technical specialties included equity compensation, FAS 109, mergers and acquisitions, due diligence, business formation, and international tax issues.

David is currently the Executive-in-Residence at the University of North Carolina-Wilmington, Cameron School of Business, having joined its faculty in the Department of Accountancy and Business Law in August 2008.

David is a licensed CPA who received his undergraduate degree from the University of New Mexico. He also completed the Ernst & Young Executive Development Program conducted by Harvard University.

Community and Board Engagements:

David has served on several community boards, many as treasurer, including: Wake Med Health & Hospitals, Inc., Wake Med Foundation, Inc., North Carolina Museum of Art Foundation, Food Bank of North Carolina, Council for Entrepreneurial Development, North Carolina Society to Prevent Blindness, and others.

Ann Murphy, PhD


Ann Murphy, PhD

Ann Murphy, PhD, is publisher and founding editor of three international, peer-reviewed journals: The Oncologist, STEM CELLS, and STEM CELLS Translational Medicine. Ann is also the founding Director General for the Society for Translational Oncology (STO).

Over its 39-year history, Ann has managed STEM CELLS, the oldest journal in the fast-paced area of stem cells and regenerative medicine research. She fosters the Journal’s excellence as it expands its size and scope as a top-tier, global peer-reviewed journal devoted to stem cell biology emphasizing mechanistic studies that have the potential to better understand disease and possible cell-based therapeutics. Ann works closely with editor-in-chief Jan A. Nolta, PhD, Institute of Regenerative Cures, UC Davis.

Over its 26-year history, Ann has guided and nurtured the growth and development of The Oncologist, the official monthly journal of STO dedicated to physicians devoted to cancer patient care. Ann has also led The Oncologist’s Continuing Medical Education (CME) Program from its inception. Ann works closely with The Oncologist’s founding editor-in-chief, Bruce A. Chabner, MD, Massachusetts General Hospital Cancer Center.

Ann is executive editor for STEM CELLS Translational Medicine (SCTM), the official journal partner of the Regenerative Medicine Foundation, the Cord Blood Association and the Regenerative Medicine Manufacturing Society. SCTM, celebrating its 10th year in 2021, bridges stem cell molecular and biological research and helps speed translation of emerging lab discoveries into clinical trials, helping move applications of these critical investigations closer to accepted best patient practices that improve outcomes. Ann works closely with SCTM’s founding editor-in-chief, Anthony Atala, MD, Director, Wake Forest Institute for Regenerative Medicine.

Ann holds a Doctorate of Philosophy with distinction in Literature from New York University. She serves on the Board of Visitors for the UNC Lineberger Comprehensive Cancer Center. She is a published authority on the Irish Literary Renaissance and the biographer of the Irish playwright and poet, Padraic Colum. A mother of five and grandmother of 10, she makes her home with her husband, Martin J. Murphy, in Durham, North Carolina.

Martin J. Murphy, DMedSc, PhD, FASCO


Martin J Murphy

Martin J. Murphy, DMedSc, PhD, FASCO was Founding CEO and Board Director of the 20-year-old non-profit CEO Roundtable on Cancer at the request of the 41st President George H.W. Bush. Marty was also Founding CEO of Project Data Sphere®, a non-profit initiative of the CEO Roundtable devoted to cancer clinical trial data-sharing and analysis. He is Founding Chief Executive Officer of the non-profit Shanghai TuoXin Health Promotion Center that has expanded its purview from cancer prevention and improving cancer patient outcomes to include international Covid-19 interventions and global pandemic preparedness.

Founding Executive Editor of the 26-year-old peer-reviewed journal, The Oncologist, Marty is also Founding Editor of Stem Cells, the 39-year-old flagship journal of stem cell biology, and Co-Founder of its 10-year-old sister journal, Stem Cells Translational Medicine reporting on stem cells in clinical trials. In 2021 he became Director Emeritus of the CEO Roundtable on Cancer. He co-chairs the Scientific & Strategic Advisory Council of the International COVID-19 Data Alliance of the Bill & Melinda Gates Foundation.

An NIH principal investigator, Marty has authored more than 180 primary peer-accepted papers and 7 books, is co-founder of Society for Translational Oncology, member of six Scientific Advisory Boards, two corporate boards of directors, Chairman Emeritus of Conquer Cancer—ASCO Foundation, and Steering Member of Chinese Society of Clinical Oncology. He is an Emeritus Member of National Cancer Policy Forum of National Academy of Medicine (US National Academy of Sciences), board member of Center for Public Health Advisory Board of the Milken Institute, Director Emeritus of Foundation for NIH, Fellow of American Society of Clinical Oncology, and former vice chairman of C-Change. Marty is married to Ann Murphy, PhD, president and founder of AlphaMed Press and co-founder and executive director of Society for Translational Oncology. They have five adult children and ten grandchildren.